The startup has developed a DNA-based CAR-TCR therapy platform that utilizes cell-directed lipid nanoparticles to integrate DNA into the target cells' genome, enhancing the durability of cell-engineered therapies. This technology aims to make these therapies more affordable and scalable, increasing accessibility for a broader patient population compared to traditional RNA-based methods.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cell-engineered therapies often rely on ex vivo cell manipulation and RNA-based methods, which can be expensive, difficult to scale, and may not provide long-lasting therapeutic effects. This limits accessibility and affordability for a broad patient population.
Solution
Nanocell Therapeutics is developing in vivo gene therapies using a non-viral, DNA-based platform to transform cell and gene therapy. The company's technology utilizes cell-directed lipid nanoparticles (LNPs) to deliver therapeutic DNA directly into target cells within the patient's body, eliminating the need for ex vivo cell manipulation. This approach aims to convert adoptive cell therapies into gene therapies, enhancing scalability, affordability, and clinical safety and efficacy. By leveraging the lasting potential of DNA, Nanocell seeks to durably modify immune-effector cells, such as T cells, directly within patients.
Target Audience
The primary target audience includes patients in need of cell and gene therapies, as well as pharmaceutical companies seeking to develop more scalable and affordable cell-based therapeutics.
Features
- Non-viral delivery method designed to specifically target and modify cells within the patient using therapeutic DNA.
- Cell-directed lipid nanoparticles (LNPs) for targeted DNA delivery.
- In vivo cell engineering to eliminate the need for ex vivo cell manipulations.
- DNA-based approach for durable modification of immune-effector cells.